Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 16/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19462040 | 1.00 | NCF1 (0.38) | NCF1CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL13752703 | 0.90 | NCF1 (0.43) | NCF1KDM4EUSP2ALDH1A1LMNA | |
| SCHEMBL1991577 | 0.89 | SMN1; SMN2 (0.41) | CHRM3CHRM2CHRM1SMN1; SMN2LMNA | |
| SCHEMBL20076238 | 0.86 | KDM4E (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL18202920 | 0.81 | KDM4E (0.30) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL1108982 | 0.81 | ALDH1A1 (0.39) | NCF1CHRM3CHRM2CHRM1SMN1; SMN2 | |
| SCHEMBL1991651 | 0.80 | GBA1 (0.36) | KDM4EUSP2ALDH1A1LMNAMMP9 | |
| SCHEMBL2551547 | 0.79 | SIGMAR1 (0.35) | — | |
| SCHEMBL23897579 | 0.79 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL18641574 | 0.78 | RBP4 (0.36) | SMN1; SMN2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-7557214-B2 | Intermediate products for producing oxazolidinone-quinolone hybrids | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2009-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | NCF1 1349/4885CHRM3 69/4885CHRM2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.